





# Should All CTOs Be Opened? PRO

Gerald S. Werner, MD, FESC, FACC, FSCAI
Klinikum Darmstadt GmbH
Darmstadt



#### Conflict of interest



 I, Gerald S. Werner, MD, have no conflict of interest to declare with regard to the following presentation



## The CTO PCI balance



- Improving angina
- Improve LV function
- Myocardial viability
- Favorable anatomical coronary factors



- PCI technical complexity
- Costly and demanding use of resources
- Requirement of skilled operators

Do it

Don't do it



## There is never a PRO without exceptions




- What we need for the indication is proof of viability
- What we need is a positive balance between the patient's impairment by the lesion and the risk of the procedure



### Good collaterals, but mixed viability in 3-VD









#### What about the REVASC Study?






The REVASC Study showed no Improvement of LV function, but the baseline EF was normal !!!

LVEF (%)			
Baseline	59.6 (45.8 to 64.3)	54.7 (42.9 to 65.1)	0.48
6-month follow-up	61.0 (51.3 to 66.8)	57.0 (45.0 to 65.5)	0.21
Change in LVEF	0.7 (-1.0 to 3.7)	0.9 (-1.3 to 4.1)	0.79









#### When to leave a CTO alone?





Is a CTO harmless because there are collaterals!

 Stable symptoms in a 55 year old: limited physical ability, occasional tightness in his breast





### Why should we open a CTO




 To let people lead a symptom-free and unaffected life ?!



## Can collaterals prevent ischemia? FFR in CTOs









## Quality of Life in OPEN-CTO



US Register with 1000 consecutive patients and at least one CTO







Efficacy: Health status @ 12 and 36 months Safety: Death, non-fatal myocardial infarction (ITT, PP) @ 36 months



## Primary Endpoint reached (ITT)




More patients were free of angina, had better quality of life and improved physical capacity EURO C






#### Even in DECISION-CTO symptoms were improved









Baseline 82 vs **77** FUP 87 vs 92 Δ5 vs 15 **71** 92 Δ 21



#### What would a medical approach achieve?



Antianginal medication: Betablocker,
Nitrates, Ca-Antagonists are not without side effects

) mg<sup>\*</sup>

2.1


-0.004

nexa

And medication needs to go on forever....

Angina Frequency (attacks/week)

Mean	3.3	2.5	
p-value vs placebo	_	0.006	




_	0.006	< 0.007	
252	262	244	
3.1	2.1	1.8	
_	0.016	< 0.001	



## But can we change the fate with a successful PCI ? ( )







#### Why should we open a CTO




- To let people lead a symptom-free and unaffected life ?!
- To make people live longer ?!



#### rSS and outcome after PCI








### Mortality and CTO-PCI: BCIS








### Mortality and CTO-PCI: BCIS






Mortality in OPEN CTO
DECISION CTO
EURO CTO



#### Mortality in DECISION-CTO








#### Mortality and CTO-PCI: BCIS





Mortality in OPEN CTO
DECISION CTO
EURO CTO



#### Why should we open a CTO



- To let people lead a symptom-free and unaffected life ?!
- To make people live longer ?!

#### Constitution of the World Health Organization: Principles

- Health is a state of complete physical, mental and social well-being and not merely the absence of disease or infirmity.
- The enjoyment of the highest attainable standard of health is one of the fundamental rights of every human being without distinction of race, religion, political belief, economic or social condition.



## The question is when **not** to open a CTO?



CTO without viable myocardium

 CTO in a small territory of ischemia without related symptoms

 CTO in a patient with severe comorbidity and limited life expectancy



#### 11th Euro CTO "Live"

5-6 Live Cases per day

#### **SAVE THE DATE**

## September 13<sup>th</sup> – 14<sup>th</sup>, 2019 Berlin, Germany

#### **Course Directors**

Gerald S. Werner, Darmstadt, Germany
Ulf Landmesser, Berlin, Germany
Alexander Bufe, Krefeld, Germany
Kambis Mashayekhi, Bad Krozingen, Germany

**Co-Course Director/Live Case Coordinator** 

Alexander Lauten, Berlin, Germany

**ECC-President** 

George Sianos, Thessaloniki, Greece

**Congress Coordinator** 

Gerald S. Werner, Darmstadt, Germany

